Answers are grounded in this paper and cite their sources.
The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding of chronic or smouldering neuroinflammation and its drivers. Recent pathological and biomarker data indicate that chronic neuroinflammation, characterised by persistent microglial activation, oxidative injury, iron and glutamate toxicity, mitochondrial dysfunction, and axonal neurodegeneration, plays a crucial role throughout the course of MS.1 Current disease-modifying therapies (DMTs) predominantly target acute inflammatory events but fail to adequately address these chronic mechanisms.
No takes yet. Share an insight, caveat, or question.
Trojano et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: